文献速递白血病

Quizartinib联合诱导和巩固化疗治疗初诊急性髓系白血病患者的1期研究

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.
PubMed 文献 · Am J Hematol · 2017-12-04

这项1期开放标签序贯分组剂量递增试验评估quizartinib联合标准方案化疗在初诊急性髓系白血病(未筛选FLT3突变状态)中的安全性和耐受性,19例患者接受三种剂量水平之一,最大耐受剂量确定为40 mg/d用14天,常见3/4级不良事件为发热性中性粒细胞减少等,16例(84%)获得缓解。

要点

  • 最大耐受剂量为quizartinib二盐酸盐40 mg/d用14天(DL-1),从化疗第4天开始口服。
  • 3例出现剂量限制性毒性:DL2组2例(1例心包积液;1例发热性中性粒细胞减少、血小板计数下降和QT间期延长),DL-1组1例(心包炎)。
  • 16例(84%)获得缓解,其中14例(74%)为复合完全缓解,2例(11%)为形态学无白血病状态。

核心结论

  • Quizartinib联合标准方案化疗在初诊急性髓系白血病中最大耐受剂量为40 mg/d用14天,未观察到联合quizartinib后明显的额外毒性,尽管在最大耐受剂量下观察到≤1级QT间期延长。
  • 3期QuANTUM-First试验正在进一步评估quizartinib联合标准方案化疗在FLT3-ITD突变初诊急性髓系白血病患者中的效果。

研究设计与样本

  • 1期、开放标签、序贯分组剂量递增试验(NCT 01390337),首次评估quizartinib联合标准方案化疗在初诊急性髓系白血病中的安全性和耐受性。
  • 19例未筛选FLT3突变状态的患者接受三种quizartinib二盐酸盐剂量水平之一:DL1为60 mg/d用7天(n=6),DL2为60 mg/d用14天(n=7),DL-1为40 mg/d用14天(n=6),从化疗第4天开始口服。
  • 中位年龄43.8岁,10例完成了诱导和巩固治疗。

主要发现

  • 3例患者出现剂量限制性毒性:DL2组2例(1例心包积液;1例发热性中性粒细胞减少、血小板计数下降和QT间期延长),DL-1组1例(心包炎)。
  • 最大耐受剂量确定为DL-1(40 mg/d用14天)。
  • 最常见的3/4级不良事件为发热性中性粒细胞减少(47%)、中性粒细胞减少(42%)、血小板减少(32%)和贫血(26%)。
  • 16例(84%)获得缓解,其中14例(74%)为复合完全缓解,2例(11%)为形态学无白血病状态。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Novel therapies have potential to improve outcomes in patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival following standard of care (SOC) cytarabine/anthracycline-based induction/consolidation chemotherapy. Quizartinib is a selective and highly potent FLT3 inhibitor that has shown strong single-agent activity in relapsed or refractory (R/R) AML. This phase 1, open-label, sequential group dose-escalation trial (NCT 01390337) is the first evaluating safety and tolerability of quizartinib in combination with SOC chemotherapy in newly diagnosed AML (ndAML). Nineteen patients unselected for FLT3 mutational status received one of three quizartinib dihydrochloride dose levels (DL): 60 mg/d for 7 days (DL1; n = 6), 60 mg/d for 14 days (DL2; n = 7), and 40 mg/d for 14 days (DL-1; n = 6); administered orally starting on day 4 of chemotherapy. Median age was 43.8 years. Ten patients completed induction and consolidation. Three patients experienced dose-limiting toxicities (DLTs): 2 at DL2 (1 pericardial effusion; 1 febrile neutropenia, decreased platelet count, and QT prolongation); 1 at DL-1 (pericarditis). Maximum tolerated dose (MTD) was identified as DL-1. Most common grade 3/4 adverse events were febrile neutropenia (47%), neutropenia (42%), thrombocytopenia (32%), and anemia (26%). There were no apparent additional toxicities with addition of quizartinib to chemotherapy although grade ≤1 QT prolongation was observed at MTD. Sixteen patients (84%) achieved a response; 14 (74%) composite complete response; 2 (11%) morphologic leukemia-free state. The phase 3 QuANTUM-First trial (NCT02668653) is further evaluating the effect of quizartinib plus SOC chemotherapy in ndAML FLT3-ITD mutated patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Altman JK, Foran JM, Pratz KW, et al. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2017. PMID: 29139135. doi:10.1002/ajh.24974

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。